Company news
Relmada Therapeutics, Inc. (NASDAQ:RLMD) news
Every Relmada Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
July 28, 2026
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
July 16, 2026
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
June 29, 2026
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
June 11, 2026
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
May 28, 2026
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
May 6, 2026
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
May 5, 2026
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
March 19, 2026
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
March 12, 2026
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 9, 2026
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
March 9, 2026
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
March 9, 2026
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Ind...
January 12, 2026
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
December 3, 2025
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
November 13, 2025
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
November 7, 2025
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
November 4, 2025
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
November 4, 2025
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of ...
October 7, 2025
Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 16, 2025
Relmada Therapeutics Issues Mid-Year CEO Letter to Shareholders
September 11, 2025
Relmada Issues Mid-Year CEO Letter to Shareholders
September 10, 2025
Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC
August 7, 2025
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
July 31, 2025
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development ...
July 15, 2025
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
June 17, 2025
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
May 8, 2025
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
April 28, 2025
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
April 27, 2025
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
April 24, 2025
Relmada Therapeutics To Present NDV-01 Data at AUA2025
April 14, 2025
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
March 27, 2025
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
March 26, 2025
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
March 25, 2025
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
February 6, 2025
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
December 9, 2024
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at it...
December 4, 2024
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
November 14, 2024
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 7, 2024
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
November 4, 2024
Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
June 18, 2024
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 8, 2024
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 19, 2024
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
March 12, 2024
Relmada Therapeutics Provides Corporate Update
January 4, 2024
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 8, 2023
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
November 3, 2023